IL-10, IL-6, and TNF-α:: Central factors in the altered cytokine network of uremia -: The good, the bad, and the ugly

被引:704
作者
Stenvinkel, P
Ketteler, M
Johnson, RJ
Lindholm, B
Pecoits-Filho, R
Riella, M
Heimbürger, O
Cederholm, T
Girndt, M
机构
[1] Karolinska Univ Hosp Huddinge, Dept Renal Med, Div Renal Med, Karolinska Inst, S-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp Huddinge, Karolinska Inst, Neurotec Dept, S-14186 Stockholm, Sweden
[3] Karolinska Univ Hosp Huddinge, Dept Renal Med, Ctr Inflammat & Haematol Res, Karolinska Inst, S-14186 Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Clin Sci, Baxter Novum, S-14186 Stockholm, Sweden
[5] Univ Hosp Aachen, Dept Nephrol & Clin Immunol, Aachen, Germany
[6] Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL USA
[7] Pontificia Univ Catolica Parana, Ctr Ciencias Biol & Saude, Curitiba, Parana, Brazil
[8] ProRenal Fdn, Renal Diabet & Hypertens Res Ctr, Curitiba, Parana, Brazil
[9] Univ Saarland, Dept Med 4, D-6650 Homburg, Germany
关键词
inflammation; IL-6; IL-10; TNF-alpha; atherosclerosis; vascular calcification;
D O I
10.1111/j.1523-1755.2005.00200.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
It has been increasingly apparent that wasting and cardiovascular disease (CVD) is associated with a persistent systemic inflammatory response in end-stage renal disease (ESRD) patients. The reasons for the increased risk of inflammation in ESRD patients appear to be complex, including nondialysis as well as dialysis-related factors. The combination of an impaired immune response coupled with persistent immune stimulation may have a role in the low-grade systemic inflammation and altered cytokine balance that characterizes the uremic state and which may translate into increased risk for vascular disease. The accelerated atherosclerotic process of ESRD may involve several interrelated processes, such as oxidative stress, endothelial dysfunction, and vascular calcification, in a milieu of constant low-grade inflammation with impaired function of neutrophils and T cells, as well as a dysregulated cytokine network. Although a large number of pro- and anti-inflammatory cytokines are of importance, available data suggest that the anti-inflammatory cytokine interleukin (IL)-10 and the mainly proinflammatory cytokines IL-6 and tumor necrosis factor-alpha (TNF-alpha) may play important roles in the development of Th imbalance, CVD and wasting in the uremic milieu. Given the strong association between proinflammatory cytokines and complications common in ESRD, such as vascular calcification and wasting, the potential role of both general and targeted anticytokine treatment strategies in ESRD patients needs further evaluation.
引用
收藏
页码:1216 / 1233
页数:18
相关论文
共 162 条
[11]  
BEMELMANS MHA, 1993, J IMMUNOL, V150, P2007
[12]   Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo [J].
Bhagat, K ;
Vallance, P .
CIRCULATION, 1997, 96 (09) :3042-3047
[13]  
Bíró L, 1998, EUR J CLIN INVEST, V28, P679
[14]   Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
HYPERTENSION, 2001, 38 (04) :938-942
[15]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[16]   Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients [J].
Bologa, RM ;
Levine, DM ;
Parker, TS ;
Cheigh, JS ;
Serur, D ;
Stenzel, KH ;
Rubin, AL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :107-114
[17]   Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines [J].
Bolton, CH ;
Downs, LG ;
Victory, JGG ;
Dwight, JF ;
Tomson, CRV ;
Mackness, MI ;
Pinkney, JH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (06) :1189-1197
[18]  
Bonafè M, 2001, EUR J IMMUNOL, V31, P2357, DOI 10.1002/1521-4141(200108)31:8<2357::AID-IMMU2357>3.3.CO
[19]  
2-O
[20]   CYTOKINE-BINDING PROTEINS IN THE LUNG [J].
BONNER, JC ;
BRODY, AR .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1995, 268 (06) :L869-L878